Dieter Walmrath
Overview
Explore the profile of Dieter Walmrath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bandorski D, Tello K, Erdal H, Sommerlad J, Wilhelm J, Vadasz I, et al.
J Clin Med
. 2023 Sep;
12(17).
PMID: 37685534
Background: Aspiration of stomach content or saliva in critical conditions-e.g., shock, intoxication, or resuscitation-can lead to acute lung injury. While various biomarkers in bronchoalveolar lavage fluids have been studied for...
2.
Gierhardt M, Pak O, Walmrath D, Seeger W, Grimminger F, Ghofrani H, et al.
Eur Respir Rev
. 2021 Sep;
30(161).
PMID: 34526314
Acute respiratory distress syndrome (ARDS) is a serious complication of severe systemic or local pulmonary inflammation, such as caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ARDS is...
3.
Schmidt R, Markart P, Ruppert C, Wygrecka M, Kuchenbuch T, Walmrath D, et al.
Respir Res
. 2007 Jul;
8:55.
PMID: 17662121
Background: Alterations to pulmonary surfactant composition have been encountered in the Acute Respiratory Distress Syndrome (ARDS). However, only few data are available regarding the time-course and duration of surfactant changes...
4.
Markart P, Ruppert C, Wygrecka M, Colaris T, Dahal B, Walmrath D, et al.
Thorax
. 2007 Feb;
62(7):588-94.
PMID: 17287298
Background: Extensive biochemical and biophysical changes of the pulmonary surfactant system occur in the acute respiratory distress syndrome (ARDS). Methods: The effect of intrabronchial administration of a recombinant surfactant protein...
5.
Schermuly R, Kreisselmeier K, Ghofrani H, Yilmaz H, Butrous G, Ermert L, et al.
Am J Respir Crit Care Med
. 2003 Sep;
169(1):39-45.
PMID: 12958054
Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of pulmonary hypertension. This study was designed to investigate chronic effects of sildenafil in monocrotaline (MCT)-induced pulmonary hypertension in...
6.
Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, et al.
Am J Respir Crit Care Med
. 2003 Mar;
167(10):1321-8.
PMID: 12615625
Infusion of fish oil-based (n-3) lipids may influence leukocyte function and plasma lipids in critical care patients. Twenty-one patients with sepsis requiring parenteral nutrition were randomized to receive an n-3...
7.
Sticher J, Scholz S, Boning O, Schermuly R, Schumacher C, Walmrath D, et al.
Anesth Analg
. 2002 Nov;
95(6):1557-62, table of contents.
PMID: 12456415
Unlabelled: Inhaled nitric oxide (NO) at 20 or 40 ppm does not improve arterial oxygenation during one-lung ventilation (OLV). The authors hypothesized that NO at smaller concentrations might improve oxygenation....
8.
Schermuly R, Schulz A, Ghofrani H, Meidow A, Rose F, Roehl A, et al.
J Pharmacol Exp Ther
. 2002 Oct;
303(2):741-5.
PMID: 12388660
Iloprost is a potent prostacyclin analog, which has been shown to exert beneficial effects in several vascular disorders. Inhalation of aerosolized iloprost was found to cause selective pulmonary vasodilatation, and...
9.
Ghofrani H, Wiedemann R, Rose F, Schermuly R, Olschewski H, Weissmann N, et al.
Lancet
. 2002 Oct;
360(9337):895-900.
PMID: 12354470
Background: Lung fibrosis can be complicated by pulmonary hypertension, limiting exercise tolerance and life expectancy. Furthermore, vasodilators might cause deterioration in gas exchange. Our aim was to compare acute effects...